

■ 23. International CML Workshop

On June 26-27, the 23. International CML Workshop will be held in Mannheim, Germany. Topics are current clinical trials and pathogenesis and management of CML in blast crisis. The workshop is followed by a EUTOS meeting focussing on the outcome and next steps of the subprojects *Molecular monitoring*, *CML Registry* and *Path to cure*. ▶ [detailed information on the workshop](#)

■ Schedule of the WP meetings at the 19th Congress of EHA

From June 12 to 15 the 19th Congress of the European Hematology Association takes place in Milan, Italy. On June 12 the ELN workpackages will meet at MiCo, Viale Eginardo (Gate 2). ▶ [schedule of WP meetings](#)

■ Publications from the Network (selected)

Acute lymphoblastic leukemia

- ▶ Della Starza I et al. Whole-genome amplification for the detection of molecular targets and minimal residual disease monitoring in acute lymphoblastic leukaemia. *Br J Haematol.* 2014 May;165(3):341-8.
- ▶ Soverini S et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. *Cancer.* 2014 Apr 1;120(7):1002-9.
- ▶ Ribera JM et al. Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial. *J Clin Oncol.* 2014 May 20;32(15):1595-604.

Acute myeloid leukemia

- ▶ Díaz-Beyá M et al. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. *Leukemia.* 2014 Apr;28(4):804-12.
- ▶ Duployez N et al. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA. *Am J Hematol.* 2014 May;89(6):610-5.
- ▶ Fasan A et al. The role of different genetic subtypes of CEBPA mutated AML. *Leukemia.* 2014 Apr;28(4):794-803.
- ▶ Fiegl M et al. Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG. *Leukemia.* 2014 May;28(5):1001-7.
- ▶ Girmenia C et al. Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. *Leuk Res.* 2014 Apr;38(4):469-74.
- ▶ Micol JB et al. Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. *Eur J Cancer.* 2014 Apr;50(6):1159-68.
- ▶ Pastore F et al. The role of therapeutic leukapheresis in hyperleukocytotic AML. *PLoS One.* 2014 Apr 14;9(4):e95062.
- ▶ Pastore F et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. *J Clin Oncol.* 2014 May 20;32(15):1586-94.

- ▶ Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. *Blood*. 2014 May 1;123(18):2777-82.
- ▶ Thépot S et al. Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. *Am J Hematol*. 2014 Apr;89(4):410-6.

Chronic myeloid leukemia

- ▶ Efficace F et al. Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. *Haematologica*. 2014 Apr;99(4):788-93.
- ▶ Efficace F et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. *Qual Life Res*. 2014 Apr;23(3):825-36.
- ▶ Gugliotta G et al. First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies. *Drugs*. 2014 Apr;74(6):627-43.
- ▶ Koskenvesa P et al. Imatinib and pegylated IFN- α 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. *Eur J Haematol*. 2014 May;92(5):413-20.
- ▶ Lauseker M et al. The impact of health care settings on survival time of patients with chronic myeloid leukemia. *Blood*. 2014 Apr 17;123(16):2494-6.
- ▶ Mughal TI et al. Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. *Haematologica*. 2014 May;99(5):797-801.
- ▶ Shah NP et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. *Blood*. 2014 Apr 10;123(15):2317-24.

Chronic lymphocytic leukemia

- ▶ Delgado J et al. New treatment options for chronic lymphocytic leukemia. *Expert Opin Pharmacother*. 2014 Apr;15(6):823-32.
- ▶ Foà R et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. *Am J Hematol*. 2014 May;89(5):480-6.
- ▶ Messina M et al. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. *Blood*. 2014 Apr 10;123(15):2378-88.
- ▶ Rossi D et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. *Blood*. 2014 Apr 3;123(14):2139-47.
- ▶ Stilgenbauer S et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. *Blood*. 2014 May 22;123(21):3247-54.

Myelodysplastic syndromes

- ▶ Alhan C et al. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. *Cytometry B Clin Cytom*. 2014 May;86(3):207-15.

Myeloproliferative neoplasms

- ▶ Barbui T et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. *Am J Hematol*. 2014 May;89(6):588-90.
- ▶ Campanelli R et al. CD14(bright)CD16(low) intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis. *Exp Hematol*. 2014 Apr;42(4):244-6.
- ▶ Gugliotta L et al. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. *Haematologica*. 2014 Apr;99(4):679-87.
- ▶ Lussana F et al. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica*. 2014 May;99(5):916-21.

- ▶ Verger E et al. TET2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosis. Br J Haematol. 2014 May;165(3):416-9.

Stem cell transplantation

- ▶ Gratwohl A et al. Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantation. Haematologica. 2014 May;99(5):908-15.
- ▶ Hefner J et al. High prevalence of distress in patients after allogeneic hematopoietic SCT: fear of progression is associated with a younger age. Bone Marrow Transplant. 2014 Apr;49(4):581-4.
- ▶ Ruggeri A et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia. 2014 Apr;28(4):779-86.

Miscellaneous

- ▶ Goasguen JE et al. Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2014 Apr;38(4):447-53.
- ▶ Gosenca D et al. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms. Genes Chromosomes Cancer. 2014 May;53(5):411-21.
- ▶ Volkert S et al. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome. Genes Chromosomes Cancer. 2014 May;53(5):402-10.
- ▶ Zini G. Stability of complete blood count parameters with storage: toward defined specifications for different diagnostic applications. Int J Lab Hematol. 2014 Apr;36(2):111-3.

■ New trials in the ELTR

TOWER A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)

ALCANTARA A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)